JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (1998) 158, 425-433       DOI: 10.1677/joe.0.1580425
© 1998 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaffrain-Rea, M.
Right arrow Articles by Gulino, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaffrain-Rea, M.
Right arrow Articles by Gulino, A
Journal of Endocrinology, Vol 158, Issue 3, 425-433
Copyright © 1998 by Society for Endocrinology


Articles

Epidermal growth factor binding sites in human pituitary macroadenomas

ML Jaffrain-Rea, E Petrangeli, C Lubrano, G Minniti, D Di Stefano, F Sciarra, L Frati, G Tamburrano, G Cantore, and A Gulino


The number of epidermal growth factor (EGF) binding sites was determined by competitive binding assays in a series of 46 pituitary macroadenomas. A single concentration of 125I-EGF (1 nM) was used for all experiments. In four cases, a displacement curve was obtained by adding increasing concentrations of cold EGF, and Scatchard analysis showed the presence of two classes of EGF binding sites, with Kd1 = 0.62 +/- 0.23 nM and Kd2 = 53.8 +/- 8.2 nM for the high- and low-affinity binding sites respectively. The distribution of EGF binding sites was studied in 42 cases by a single-point assay, in the presence and in the absence of a 100-fold cold EGF excess. A non-parametric distribution of EGF binding sites was observed (median 10.2 fmol/mg membrane protein, range 0.0-332.0). EGF-receptor positivity, defined as EGF binding > or = 10.0 fmol/mg protein, was observed in 23 samples (54.8%), especially in prolactinomas (76.5%, P < 0.05 vs other tumors taken together) and in gonadotrope adenomas (62.5%). EGF binding was higher in invasive than in non-invasive adenomas (median: 12.8 vs 0.0 fmol/mg membrane protein, P = 0.047), and especially in adenomas invading the sphenoid sinus (median 26.7 fmol/mg membrane protein, P = 0.008 vs other adenomas). EGF binding also tended to increase with the grade of supra/extrasellar extension according to Wilson (P = 0.15). Sex steroid receptors (SSRs) were simultaneously determined in both cytosolic and nuclear fractions of 31 pituitary adenomas. Estrogen and progesterone receptors were determined by an enzyme-linked immunoassay and androgen receptors by a competitive binding assay with [3H]methyltrienolone. No correlation could be found between EGF binding and either the gender and gonadal status of the patients, or the expression of SSRs by the adenomas. We conclude that the EGF family of growth factors may play a role in the evolution of a significant subset of human pituitary adenomas, especially in their invasiveness, and that a high EGF binding capacity may represent an additional marker of aggressiveness for these tumors. Sex steroids do not appear to have a significant role in the regulation of EGF binding in vivo in these tumors.


This article has been cited by other articles:


Home page
Cancer Res.Home page
G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.-G. Ren, and S. Melmed
Rat Prolactinoma Cell Growth Regulation by Epidermal Growth Factor Receptor Ligands
Cancer Res., August 1, 2008; 68(15): 6377 - 6386.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Miller, S. Chen, J. Woodliff, and S. Kansra
Curcumin (Diferuloylmethane) Inhibits Cell Proliferation, Induces Apoptosis, and Decreases Hormone Levels and Secretion in Pituitary Tumor Cells
Endocrinology, August 1, 2008; 149(8): 4158 - 4167.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A. Gurlek, N. Karavitaki, O. Ansorge, and J. A H Wass
What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics
Eur. J. Endocrinol., February 1, 2007; 156(2): 143 - 153.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
I. M. Hussaini, C. Trotter, Y. Zhao, R. Abdel-Fattah, S. Amos, A. Xiao, C. U. Agi, G. T. Redpath, Z. Fang, G. K.K. Leung, et al.
Matrix Metalloproteinase-9 Is Differentially Expressed in Nonfunctioning Invasive and Noninvasive Pituitary Adenomas and Increases Invasion in Human Pituitary Adenoma Cell Line
Am. J. Pathol., January 1, 2007; 170(1): 356 - 365.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
G. Vlotides, M. Cruz-Soto, T. Rubinek, T. Eigler, C. J. Auernhammer, and S. Melmed
Mechanisms for Growth Factor-Induced Pituitary Tumor Transforming Gene-1 Expression in Pituitary Folliculostellate TtT/GF Cells
Mol. Endocrinol., December 1, 2006; 20(12): 3321 - 3335.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
M Theodoropoulou, T Arzberger, Y Gruebler, M L Jaffrain-Rea, J Schlegel, L Schaaf, E Petrangeli, M Losa, G K Stalla, and U Pagotto
Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells
J. Endocrinol., November 1, 2004; 183(2): 385 - 394.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. L. Peghini, M. Iwamoto, M. Raffeld, Y.-J. Chen, S. U. Goebel, J. Serrano, and R. T. Jensen
Overexpression of Epidermal Growth Factor and Hepatocyte Growth Factor Receptors in a Proportion of Gastrinomas Correlates with Aggressive Growth and Lower Curability
Clin. Cancer Res., July 1, 2002; 8(7): 2273 - 2285.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society for Endocrinology.